These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
203 related articles for article (PubMed ID: 17637534)
1. [Treatments of pancreatic cancer from the standpoint of medical oncology]. Furuse J; Ishii H; Nakachi K; Suzuki E; Shimizu S Gan To Kagaku Ryoho; 2007 Jul; 34(7):997-1001. PubMed ID: 17637534 [TBL] [Abstract][Full Text] [Related]
2. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia. Li Y; Sun J; Jiang Z; Zhang L; Liu G J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948 [TBL] [Abstract][Full Text] [Related]
3. Improved survival with combined gemcitabine and S-1 for locally advanced pancreatic cancer: pooled analysis of three randomized studies. Yanagimoto H; Ishii H; Nakai Y; Ozaka M; Ikari T; Koike K; Ueno H; Ioka T; Satoi S; Sho M; Okusaka T; Tanaka M; Shimokawa T; Kwon AH; Isayama H J Hepatobiliary Pancreat Sci; 2014 Oct; 21(10):761-6. PubMed ID: 24925464 [TBL] [Abstract][Full Text] [Related]
4. Comparative Outcomes of First-Line Chemotherapy for Metastatic Pancreatic Cancer Among the Regimens Used in Japan: A Systematic Review and Network Meta-analysis. Takumoto Y; Sasahara Y; Narimatsu H; Akazawa M JAMA Netw Open; 2022 Jan; 5(1):e2145515. PubMed ID: 35099549 [TBL] [Abstract][Full Text] [Related]
5. Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer. Nakata B; Amano R; Nakao S; Tamura T; Shinto O; Hirakawa T; Okita Y; Yamada N; Hirakawa K J Exp Clin Cancer Res; 2010 Feb; 29(1):15. PubMed ID: 20181235 [TBL] [Abstract][Full Text] [Related]
6. Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts. Nakahira S; Nakamori S; Tsujie M; Takeda S; Sugimoto K; Takahashi Y; Okami J; Marubashi S; Miyamoto A; Takeda Y; Nagano H; Dono K; Umeshita K; Sakon M; Monden M Anticancer Res; 2008; 28(1A):179-86. PubMed ID: 18383843 [TBL] [Abstract][Full Text] [Related]
7. Retrospective study of gemcitabine plus S-1 versus gemcitabine alone in cases with unresectable advanced pancreatic cancer. Suzuki S; Ozaki Y; Saida S; Kaji S; Koike N; Harada N; Hayashi T; Suzuki M Hepatogastroenterology; 2013 Jun; 60(124):916-20. PubMed ID: 23478143 [TBL] [Abstract][Full Text] [Related]
8. S-1 in the treatment of pancreatic cancer. Sudo K; Nakamura K; Yamaguchi T World J Gastroenterol; 2014 Nov; 20(41):15110-8. PubMed ID: 25386059 [TBL] [Abstract][Full Text] [Related]
9. Gemcitabine, oxaliplatin, and capecitabine (GEMOXEL) compared with gemcitabine alone in metastatic pancreatic cancer: a randomized phase II study. Petrioli R; Roviello G; Fiaschi AI; Laera L; Marrelli D; Roviello F; Francini E Cancer Chemother Pharmacol; 2015 Apr; 75(4):683-90. PubMed ID: 25618415 [TBL] [Abstract][Full Text] [Related]
11. [A case of advanced pancreatic cancer responding well to S-1/gemcitabine combination therapy after gemcitabine therapy]. Kuji M; Yamamoto Y; Tani C; Kenno S; Kobayashi T Gan To Kagaku Ryoho; 2011 May; 38(5):853-5. PubMed ID: 21566453 [TBL] [Abstract][Full Text] [Related]
12. [Efficacy of gemcitabine-based chemotherapy on advanced pancreatic cancer]. Gong JF; Zhang XD; Li J; Di LJ; Jin ML; Shen L Ai Zheng; 2007 Aug; 26(8):890-4. PubMed ID: 17697554 [TBL] [Abstract][Full Text] [Related]
13. The addition of S-1 to gemcitabine-based chemotherapy improves survival with increased toxicity for patients with advanced pancreatic cancer: combined meta-analysis of efficacy and safety profile. Liu Y; Huang QK; Hong WD; Wu JM; Sun XC Clin Res Hepatol Gastroenterol; 2015 Apr; 39(2):254-60. PubMed ID: 25304193 [TBL] [Abstract][Full Text] [Related]
14. Current oncological treatment of patients with pancreatic cancer in germany: results from a national survey on behalf of the Arbeitsgemeinschaft Internistische Onkologie and the Chirurgische Arbeitsgemeinschaft Onkologie of the Germany Cancer Society. Boeck S; Bruns CJ; Sargent M; Schafer C; Seufferlein T; Jauch KW; Heinemann V Oncology; 2009; 77(1):40-8. PubMed ID: 19556808 [TBL] [Abstract][Full Text] [Related]
16. Treatment of advanced pancreatic cancer. Ducreux M; Boige V; Malka D Semin Oncol; 2007 Apr; 34(2 Suppl 1):S25-30. PubMed ID: 17449349 [TBL] [Abstract][Full Text] [Related]
17. [Current status and future directions of chemotherapy for pancreatic cancer]. Furuse J Nihon Shokakibyo Gakkai Zasshi; 2013 Dec; 110(12):2060-5. PubMed ID: 24305093 [No Abstract] [Full Text] [Related]
18. [A case of Complete Response(CR)to combination therapy of S-1 and Gemcitabine(GEM)for unresectable pancreatic cancer]. Miyagawa K; Yata Y; Yamaoka N; Sagara Y Gan To Kagaku Ryoho; 2010 Jun; 37(6):1145-7. PubMed ID: 20567125 [TBL] [Abstract][Full Text] [Related]
19. Any progress in the management of advanced pancreatic cancer? Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009. Li J; Saif MW JOP; 2009 Jul; 10(4):361-5. PubMed ID: 19581735 [TBL] [Abstract][Full Text] [Related]
20. [Clinical benefit of full-dose gemcitabine for advanced pancreatic cancer refractory to S-1+gemcitabine]. Hachisuka H; Takahashi M; Kushima A; Nakamoto T; Takahashi K; Iwamura Y; Wakata M; Nagano K; Nakajima T; Nunomura M; Araki K Gan To Kagaku Ryoho; 2013 May; 40(5):639-42. PubMed ID: 23863590 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]